255 related articles for article (PubMed ID: 11475149)
21. Differential diagnosis between secondary and tertiary hyperparathyroidism in a case of a giant-cell and brown tumor containing mass. Findings by (99m)Tc-MDP, (18)F-FDG PET/CT and (99m)Tc-MIBI scans.
Gedik GK; Ata O; Karabagli P; Sari O
Hell J Nucl Med; 2014; 17(3):214-7. PubMed ID: 25397627
[TBL] [Abstract][Full Text] [Related]
22. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
Ak I; Aslan V; Vardareli E; Gülbaş Z
Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
[TBL] [Abstract][Full Text] [Related]
23. Dual-phase (99m)Tc-MIBI scintigraphy with delayed neck and thorax SPECT/CT and bone scintigraphy in patients with primary hyperparathyroidism: correlation with clinical or pathological variables.
Qiu ZL; Wu B; Shen CT; Zhu RS; Luo QY
Ann Nucl Med; 2014 Oct; 28(8):725-35. PubMed ID: 25120244
[TBL] [Abstract][Full Text] [Related]
24. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma.
Mileshkin L; Blum R; Seymour JF; Patrikeos A; Hicks RJ; Prince HM
Eur J Haematol; 2004 Jan; 72(1):32-7. PubMed ID: 14962260
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Tc-99m methylene diphosphonate, Tc-99m human immune globulin, and Tc-99m-labeled white blood cell scintigraphy in the diabetic foot.
Unal SN; Birinci H; Baktiroğlu S; Cantez S
Clin Nucl Med; 2001 Dec; 26(12):1016-21. PubMed ID: 11711704
[TBL] [Abstract][Full Text] [Related]
26. Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP.
Caner B; Kitapçl M; Unlü M; Erbengi G; Calikoğlu T; Göğüş T; Bekdik C
J Nucl Med; 1992 Mar; 33(3):319-24. PubMed ID: 1531501
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow immunoscintigraphy using technetium-99m anti-granulocyte antibody in multiple myeloma.
Sohn SK; Ahn BC; Lee SW; Kim DH; Chun KA; Kim JG; Park SH; Song HS; Lee B; Lee J
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):591-6. PubMed ID: 11976796
[TBL] [Abstract][Full Text] [Related]
28. Hepatic and splenic uptake of Tc-99m HDP in multiple myeloma: additional findings on Tc-99m MIBI and Tc-99m sulfur colloid images.
Berk F; Demir H; Hacihanefioglu A; Arslan A; Erdincler O; Isgoren S; Aktolun C
Ann Nucl Med; 2002 Apr; 16(2):137-41. PubMed ID: 12043908
[TBL] [Abstract][Full Text] [Related]
29. 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumours of the extremities.
Moustafa H; Riad R; Omar W; Zaher A; Ebied E
Q J Nucl Med; 2003 Mar; 47(1):51-7. PubMed ID: 12714955
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma.
Hung GU; Tsai CC; Tsai SC; Lin WY
Anticancer Res; 2005; 25(6C):4737-41. PubMed ID: 16334169
[TBL] [Abstract][Full Text] [Related]
31. The comparison of dual phase Tc-99m MIBI and tc-99m MDP scintimammography in the evaluation of breast masses: preliminary report.
Arslan N; Ozturk E; Ilgan S; Narin Y; Dundar S; Tufan T; Pekcan M; Bayhan H
Ann Nucl Med; 2000 Feb; 14(1):39-46. PubMed ID: 10770579
[TBL] [Abstract][Full Text] [Related]
32. Reverse of the differential uptake intensity of Tc-99m MIBI and Tc-99m V-DMSA by multiple myeloma lesions in response to therapy.
Athanasoulis T; Koutsikos J; Moulopoulos LA; Tsiouris S; Dimopoulos MA; Zerva C
Clin Nucl Med; 2003 Aug; 28(8):631-5. PubMed ID: 12897645
[TBL] [Abstract][Full Text] [Related]
33. Correlation of 99mTc-sestamibi uptake with blood-pool and osseous phase 99mTc-MDP uptake in malignant bone and soft-tissue tumours.
Ozcan Z; Burak Z; Erinç R; Dirlik A; Başdemir G; Sabah D; Ozkiliç H
Nucl Med Commun; 2001 Jun; 22(6):679-83. PubMed ID: 11403180
[TBL] [Abstract][Full Text] [Related]
34. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
35. Intraindividual Comparison of
Rathke H; Afshar-Oromieh A; Giesel FL; Kremer C; Flechsig P; Haufe S; Mier W; Holland-Letz T; De Bucourt M; Armor T; Babich JW; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
[TBL] [Abstract][Full Text] [Related]
36. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
37. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
Rubello D; Mazzarotto R; Casara D
Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up.
Pace L; Catalano L; Del Vecchio S; Di Gennaro F; De Renzo A; Sica G; Califano C; Tedesco N; Borrelli G; Rotoli B; Salvatore M
Eur J Nucl Med; 2001 Mar; 28(3):304-12. PubMed ID: 11315597
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Tc-99m sestamibi and TI-201 uptake in multiple myeloma.
Chun KA; Cho IH; Won KC; Lee KH; Lee HW; Hyun MS; Hayashida K
Clin Nucl Med; 2001 Mar; 26(3):212-5. PubMed ID: 11245112
[TBL] [Abstract][Full Text] [Related]
40. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
